SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Bone Biologics Corporation BBLG NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Bone Biologics Corporation (BBLG) is a Medical - Devices company in the Healthcare sector, currently trading at $1.26. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: BBLG trades at a trailing Price-to-Earnings (P/E) of -0.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.03.

Net income is $3M (loss), growing at -141.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $5M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 13.85 (strong liquidity). Debt-to-assets is 0%. Total assets: $6M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

BBLG SharesGrow Score Overview

61/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BBLG

BBLG trades at a trailing Price-to-Earnings (P/E) of -0.5 (S&P 500 average ~25). Forward PEG 0.03 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.08. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

BBLG: +0%/yr revenue is, -141.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet BBLG: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 13.85 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

BBLG: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range1.05-6.75

Volume3.65K

Avg Volume (30D)21.82K

Market Cap$2.26M

Beta (1Y)0.42

Share Statistics

EPS (TTM)-2.65

Shares Outstanding$1.17M

IPO Date2021-10-13

Employees2

CEOJeffrey Frelick

Financial Highlights & Ratios

EBITDA$-3.11M

Net Income$-3.11M

Operating Income$-3.23M

Total Cash$5.33M

Net Debt$-5.33M

Total Assets$5.8M

Price / Earnings (P/E)-0.5

Analyst Forecast

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS0980706008

Price Chart

BBLG

Bone Biologics Corporation ↗ · NASDAQ Capital Marke

Healthcare • Medical - Devices

1.05 52WK RANGE 6.75

People Also View

Rapid Micro Biosystems, Inc.

Vivos Therapeutics, Inc.

Sintx Technologies, Inc.

Tenon Medical, Inc.

Talis Biomedical Corporation

Heart Test Laboratories, Inc.

Ra Medical Systems, Inc.

INVO Bioscience, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message